Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 5/20 | 0.42 |
| ▸ | LDHB | P07195 | 3/20 | 0.42 |
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490218 | 1.00 | EGFR (0.49) | EGFRKDRPDGFRBKDM4EALDH1A1 | |
| SCHEMBL22862554 | 0.89 | EGFR (0.46) | EGFRKDRPDGFRBKDM4EALDH1A1 | |
| SCHEMBL22862715 | 0.89 | LDHA (0.45) | EGFRKDRLDHALDHB | |
| SCHEMBL29490352 | 0.89 | LDHA (0.45) | EGFRKDRLDHALDHB | |
| SCHEMBL29490306 | 0.89 | EGFR (0.46) | EGFRKDRPDGFRBKDM4EALDH1A1 | |
| SCHEMBL22862964 | 0.83 | EGFR (0.50) | EGFRKDRPDGFRBKDM4EALDH1A1 | |
| SCHEMBL29490226 | 0.83 | EGFR (0.50) | EGFRKDRPDGFRBKDM4EALDH1A1 | |
| SCHEMBL22862686 | 0.83 | EGFR (0.50) | EGFRKDRPDGFRBKDM4EKRAS | |
| SCHEMBL29490225 | 0.83 | EGFR (0.50) | EGFRKDRPDGFRBKDM4EKRAS | |
| SCHEMBL22862570 | 0.78 | RAB9A (0.38) | EGFRKDRPDGFRBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | EGFR 3230/4885KDR 3642/4885PDGFRB 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.